Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab - PubMed
3 days ago
- #inflammatory bowel disease
- #treat-to-target
- #pharmacist-led care
- Pharmacist-led treat-to-target approach improves IBD patient care with upadacitinib or risankizumab.
- Retrospective study (Aug-Dec 2023) included 437 IBD patients; follow-up success rate was 84%.
- IBD pharmacist made 3512 interventions, focusing on therapy continuation and lab monitoring.
- Therapy discontinuations commonly occurred between 12 weeks and 6 months post-initiation.
- Findings highlight pharmacist role in continuity of care and tracking progress in treat-to-target strategy.